These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 15970469

  • 1. Infection and inflammation in cystic fibrosis: a short review.
    Heijerman H.
    J Cyst Fibros; 2005 Aug; 4 Suppl 2():3-5. PubMed ID: 15970469
    [Abstract] [Full Text] [Related]

  • 2. Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies.
    Kukavica-Ibrulj I, Levesque RC.
    Lab Anim; 2008 Oct; 42(4):389-412. PubMed ID: 18782827
    [Abstract] [Full Text] [Related]

  • 3. Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens.
    Davidson DJ, Dorin JR, McLachlan G, Ranaldi V, Lamb D, Doherty C, Govan J, Porteous DJ.
    Nat Genet; 1995 Apr; 9(4):351-7. PubMed ID: 7540910
    [Abstract] [Full Text] [Related]

  • 4. Challenging and emerging pathogens in cystic fibrosis.
    de Vrankrijker AM, Wolfs TF, van der Ent CK.
    Paediatr Respir Rev; 2010 Dec; 11(4):246-54. PubMed ID: 21109184
    [Abstract] [Full Text] [Related]

  • 5. Cytokines and inflammatory mediators in cystic fibrosis.
    Courtney JM, Ennis M, Elborn JS.
    J Cyst Fibros; 2004 Dec; 3(4):223-31. PubMed ID: 15698939
    [Abstract] [Full Text] [Related]

  • 6. Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis.
    Ramsey DM, Wozniak DJ.
    Mol Microbiol; 2005 Apr; 56(2):309-22. PubMed ID: 15813726
    [Abstract] [Full Text] [Related]

  • 7. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?
    Chmiel JF, Davis PB.
    Respir Res; 2003 Apr; 4(1):8. PubMed ID: 14511398
    [Abstract] [Full Text] [Related]

  • 8. [Pathogenesis and novel possibilities of diagnosis of cystic fibrosis].
    Kilian K, Kisiel BM.
    Pol Merkur Lekarski; 2006 May; 20(119):582-5. PubMed ID: 16875168
    [Abstract] [Full Text] [Related]

  • 9. Acute Pseudomonas challenge in cystic fibrosis mice causes prolonged nuclear factor-kappa B activation, cytokine secretion, and persistent lung inflammation.
    Saadane A, Soltys J, Berger M.
    J Allergy Clin Immunol; 2006 May; 117(5):1163-9. PubMed ID: 16675347
    [Abstract] [Full Text] [Related]

  • 10. Update on treatment of pulmonary exacerbations in cystic fibrosis.
    Smyth A.
    Curr Opin Pulm Med; 2006 Nov; 12(6):440-4. PubMed ID: 17053495
    [Abstract] [Full Text] [Related]

  • 11. Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis.
    Hogardt M, Hoboth C, Schmoldt S, Henke C, Bader L, Heesemann J.
    J Infect Dis; 2007 Jan 01; 195(1):70-80. PubMed ID: 17152010
    [Abstract] [Full Text] [Related]

  • 12. The clinical approach to lung disease in patients with cystic fibrosis.
    O'Sullivan BP, Flume P.
    Semin Respir Crit Care Med; 2009 Oct 01; 30(5):505-13. PubMed ID: 19760538
    [Abstract] [Full Text] [Related]

  • 13. [Pseudomonas aeruginosa infection in cystic fibrosis. The importance of early antibiotic therapy].
    Dutau G, Brémont F.
    Rev Mal Respir; 1990 Oct 01; 7(3):183-5. PubMed ID: 2114027
    [No Abstract] [Full Text] [Related]

  • 14. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN, Ratjen F.
    Semin Respir Crit Care Med; 2009 Oct 01; 30(5):587-95. PubMed ID: 19760546
    [Abstract] [Full Text] [Related]

  • 15. Dynamics of adaptive microevolution of hypermutable Pseudomonas aeruginosa during chronic pulmonary infection in patients with cystic fibrosis.
    Hoboth C, Hoffmann R, Eichner A, Henke C, Schmoldt S, Imhof A, Heesemann J, Hogardt M.
    J Infect Dis; 2009 Jul 01; 200(1):118-30. PubMed ID: 19459782
    [Abstract] [Full Text] [Related]

  • 16. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Ratjen F.
    Curr Opin Pulm Med; 2006 Nov 01; 12(6):428-32. PubMed ID: 17053493
    [Abstract] [Full Text] [Related]

  • 17. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis.
    Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kürthy G, Schmid KW, Weller M, Tümmler B, Lang F, Grassme H, Döring G, Gulbins E.
    Nat Med; 2008 Apr 01; 14(4):382-91. PubMed ID: 18376404
    [Abstract] [Full Text] [Related]

  • 18. Role of CFTR, Pseudomonas aeruginosa and Toll-like receptors in cystic fibrosis lung inflammation.
    Buchanan PJ, Ernst RK, Elborn JS, Schock B.
    Biochem Soc Trans; 2009 Aug 01; 37(Pt 4):863-7. PubMed ID: 19614608
    [Abstract] [Full Text] [Related]

  • 19. Oxygen, cyanide and energy generation in the cystic fibrosis pathogen Pseudomonas aeruginosa.
    Williams HD, Zlosnik JE, Ryall B.
    Adv Microb Physiol; 2007 Aug 01; 52():1-71. PubMed ID: 17027370
    [Abstract] [Full Text] [Related]

  • 20. Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation.
    Bonvillain RW, Valentine VG, Lombard G, LaPlace S, Dhillon G, Wang G.
    J Heart Lung Transplant; 2007 Sep 01; 26(9):890-7. PubMed ID: 17845927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.